Previous 10 | Next 10 |
Vinco Ventures (NASDAQ:BBIG) +65%. Aterian (NASDAQ:ATER) +52%. Support.com (NASDAQ:SPRT) +45%. Affirm Holdings (NASDAQ:AFRM) +40% as Amazon to integrate pay-over-time into its cart Globalstar (NYSE:GSAT) +36% on report iPhone 13 may use satellite connectivity Katapult...
New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure. Guidance underscores the benefits of SGLT inhibitors in significantly reducing risk of death due to cardiovascular ca...
Rapid benefit of sotagliflozin supported by data from the SOLOIST and SCORED trials presented at ESC Congress 2021 - The Digital Experience, including: 33% absolute risk reduction in the composite cardiovascular endpoint in type 2 diabetes patients with acute decompensated heart...
Lexicon Pharmaceuticals (NASDAQ:LXRX) has filed for a $200M mixed shelf offering composed of common stock, preferred stock, debt securities, warrants, rights, and units. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company's two lead candida...
The biggest news item from Lexicon's second quarter report was a delay in expected results from the company's Phase II studies of LX9211 in pain on slower enrollment. Lexicon is using a tougher screening process for patients in the LX9211 studies, which should help reduce the risk of ...
Lexicon Pharmaceuticals (NASDAQ:LXRX): Q2 GAAP EPS of -$0.13 beats by $0.03. Revenue of $0.2M (-97.8% Y/Y) beats by $0.19M. As of June 30, 2021, Lexicon had $118.5M in cash and investments, as compared to $152.3M as of December 31, 2020. Press Release For further details see: Lexicon Ph...
Biopharmaceutical company Lexicon Pharmaceuticals (NASDAQ:LXRX) has appointed Craig Granowitz as Senior Vice President and Chief Medical Officer, effective August 2, 2021. Granowitz was previously Chief Medical Officer at Amarin (NASDAQ:AMRN). In the new role, Granowitz will oversee the ...
THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Craig Granowitz, M.D., Ph.D. will join the company as senior vice president and chief medical officer, effective August 2, 2021. Dr. Granowitz joins Lexicon wit...
THE WOODLANDS, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended June 30, 2021 and provided an update on key milestones. “We remain on track to submit our New Drug Applicati...
THE WOODLANDS, Texas, July 28, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its second quarter 2021 financial results on Friday, July 30, 2021 before the markets open. Management will conduct a conference call and live webcast at 8:00 a.m. ET (...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...